Loading...
OTC Markets
Totals
Securities
12,214
Dollar Vol
$2.7B
Share Vol
3.1B
Trades
358,241

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

ENZC
Enzolytics Inc.

Common Stock

0.0007

-0.0001

-12.50%

0.0007 / 0.0008 (1 x 1)

Real-Time Best Bid & Ask: 05:00pm 07/18/2025
Delayed (15 Min) Trade Data: 03:35pm 07/18/2025

Enzolytics Inc.

1101 RAINTREE CIRCLE STE 130

ALLEN, TX 75013

Principal Executive Offices:

1101 RAINTREE CIRCLE STE 130

ALLEN, TX 75013

Business Description
Business Description Enzolytics, Inc. (the "Company" or "ENZC") is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company is committed to creating drugs for the better health of mankind. ENZC's flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, ...
More
Financial Reporting
Reporting Status
Alternative Reporting Standard
Audited Financials
Unaudited
CIK
0001421851
Fiscal Year End
12/31
Company Officers & Contacts
Diana Zhabilov
CFO, CEO

Harry H. Zhabilov , Jr.
CSO, Company Secretary

Harry H. Zhabilov has served as Chairman, President & Chief Science Officer at Immunotech Laboratories, Inc., Chairman, President & Chief Executive Officer for Enzolytics, Inc. and Treasurer & Chief Science Officer at Bassline Productions, Inc. Mr. Zhabilov is a Member of American Institute of Chemical Engineers and Member of American ChemicalSociety. Mr. Zhabilov previously was Executive Vice President at VG Life Sciences, Inc., Vice Chairman, Secretary & Chief Science Officer at International Technology Systems, Inc. and Research Scientist at Bulgarian Academy of the Sciences. Mr. Zhabilov has extensive experience in protein isolation and purification in immunochemistry and biochemistry along with experience with therapeutic proteins used in HIV and cancer. Mr. Zhabilov also has experience in the preparation of an application for a nutraceutical compound/supplement for the FDA. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company's IPF platform. Mr. Zhabilov has also managed several clinical trials utilizing therapeutic proteins.

Kelli Austin
Accountant

Board of Directors
Lachezar Ivanov
Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Harry H. Zhabilov , Jr.
Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Harry H. Zhabilov has served as Chairman, President & Chief Science Officer at Immunotech Laboratories, Inc., Chairman, President & Chief Executive Officer for Enzolytics, Inc. and Treasurer & Chief Science Officer at Bassline Productions, Inc. Mr. Zhabilov is a Member of American Institute of Chemical Engineers and Member of American ChemicalSociety. Mr. Zhabilov previously was Executive Vice President at VG Life Sciences, Inc., Vice Chairman, Secretary & Chief Science Officer at International Technology Systems, Inc. and Research Scientist at Bulgarian Academy of the Sciences. Mr. Zhabilov has extensive experience in protein isolation and purification in immunochemistry and biochemistry along with experience with therapeutic proteins used in HIV and cancer. Mr. Zhabilov also has experience in the preparation of an application for a nutraceutical compound/supplement for the FDA. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company's IPF platform. Mr. Zhabilov has also managed several clinical trials utilizing therapeutic proteins.

Diana Zhabilov
CFO, CEO

Other Company Insiders
Felizian Paul
Diana Zhabilov (Trustee)
Zhabilov Trust
Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
Mallett & Barnes Tax Service

6136 Mission Gorge Road

Suite 125

San Diego, CA 92120

Accounting/Auditing Firm
Fruci & Associates II, PLLC

802 N. Washington St.

Spokane, WA 99201

Securities Counsel
Morgan E. Petitti, Esq.

118 W. Streetsboro Road

Suite #317

Hudson, OH 44236

Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US, 2007

TX, US, 2004

Employees
6 as of 08/02/2021
Shell
No
Products and Services

The Company’s products consist of two distinct drug development proprietary technologies: Immunotherapy and fully human monoclonal antibodies. Enzolytics has proprietary technology for creating human cell lines that produce fully human monoclonal antibodies against numerous infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (Coronavirus) monoclonal antibodies for treating COVID-19. The Company plans to employ its technology to subsequently produce fully human monoclonal antibodies for treating HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus. The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).

Company Facilities

The Company leases a 380 sq ft facility located at 2000 North Central Expressway Plano Texas 75074 for $650.00 per month. The lease was for a one-year period ending on June 30, 2021, and is currently month to month. All lease payments are current. In addition, the Company leases a 695 sq ft office and laboratory facility located at 800 Raymond Stotzer Parkway Building 1904, Suite 2106, College Station, Texas 77843 for $2,595.00 per month. The lease is for a one-year period ending in December 2022.

Company Notes
Formerly=Eco-Petroleum Solutions, Inc. until 3-2018
Formerly=Structural Enhancement Technologies Corp. until 2-2013
Formerly=Extreme Mobile Coatings Worldwide Corp. until 6-2010
Formerly=Extreme Mobile Coatings Corp Ltd. until 4-2009
Formerly=Falcon Media Services Ltd. until 11-2008
OTCID Market Logo
OTCID
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.